Technical Analysis for ARWR - Arrowhead Research Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 22.12 | 1.14% | 0.25 |
Earnings due: Apr 30
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 1.14% | |
Down 3 Days in a Row | Weakness | 1.14% | |
Gapped Down | Weakness | 1.14% | |
MACD Bullish Signal Line Cross | Bullish | -5.02% | |
Wide Bands | Range Expansion | -5.02% | |
Shooting Star Candlestick | Bearish | -6.98% |
Alert | Time |
---|---|
Possible NR7 | about 16 hours ago |
Possible Inside Day | about 16 hours ago |
Up 2% | about 20 hours ago |
Up 1% | about 20 hours ago |
Lower Bollinger Band Support | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 04/30/2024
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hepatitis B Virus Chronic Hbv Infection Rna Therapeutics Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 42.48 |
52 Week Low | 20.67 |
Average Volume | 1,246,758 |
200-Day Moving Average | 29.02 |
50-Day Moving Average | 28.00 |
20-Day Moving Average | 24.53 |
10-Day Moving Average | 23.01 |
Average True Range | 1.26 |
RSI (14) | 32.43 |
ADX | 29.85 |
+DI | 15.99 |
-DI | 35.90 |
Chandelier Exit (Long, 3 ATRs) | 25.29 |
Chandelier Exit (Short, 3 ATRs) | 25.18 |
Upper Bollinger Bands | 27.99 |
Lower Bollinger Band | 21.08 |
Percent B (%b) | 0.15 |
BandWidth | 28.17 |
MACD Line | -1.63 |
MACD Signal Line | -1.59 |
MACD Histogram | -0.0413 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 23.08 | ||||
Resistance 3 (R3) | 23.05 | 22.71 | 22.92 | ||
Resistance 2 (R2) | 22.71 | 22.46 | 22.72 | 22.87 | |
Resistance 1 (R1) | 22.41 | 22.31 | 22.44 | 22.44 | 22.81 |
Pivot Point | 22.07 | 22.07 | 22.08 | 22.08 | 22.07 |
Support 1 (S1) | 21.77 | 21.82 | 21.80 | 21.80 | 21.43 |
Support 2 (S2) | 21.43 | 21.67 | 21.44 | 21.37 | |
Support 3 (S3) | 21.13 | 21.43 | 21.32 | ||
Support 4 (S4) | 21.16 |